How lurbinectedin performs in advanced small cell lung cancer
Lurbinectedin (Zepzelca), approved by the FDA in 2020 for metastatic small cell lung cancer (SCLC) after platinum-based chemotherapy, shows response rates of 35% in pretreated patients. Median overall survival reaches 9.3 months versus 5.3 months with standard chemotherapy (investigator's choice), based on the phase 3 ATLANTIS trial. Progression-free survival is 4.1 months compared to 3.7 months.[1][2]
Response rates and survival data from key trials
In the phase 2 basket trial (across multiple tumor types), overall response rate was 21%, with 46% in SCLC. Median duration of response was 5.1 months in SCLC. For platinum-resistant SCLC specifically, responses hit 35% with median survival of 11.6 months.[3] Real-world data from 2021-2023 studies confirm similar outcomes, with 30-40% disease control rates in heavily pretreated patients.[1]
Does it work in other late-stage cancers?
Limited efficacy outside SCLC. In phase 2 trials:
- Platinum-resistant ovarian cancer: 25% response rate, median survival 15.4 months.
- Uterine leiomyosarcoma: 12% response.
- Triple-negative breast cancer: 0% response.
No approvals beyond SCLC; ongoing trials test combinations in mesothelioma, colorectal, and neuroendocrine cancers, but monotherapy responses stay below 20%.[3][4]
How it compares to other late-stage treatments
Versus topotecan (standard second-line SCLC therapy), lurbinectedin extends survival by about 4 months with less toxicity.[2] It outperforms irinotecan in progression-free survival but matches overall survival. In combinations (e.g., with doxorubicin), response rates climb to 50% in sarcomas, though not yet standard.[1][5]
Common side effects in late-stage patients
Hematologic toxicity leads: neutropenia (52%), anemia (45%), thrombocytopenia (33%). Non-hematologic issues include fatigue (35%), nausea (28%), decreased appetite (23%). Myelosuppression causes most discontinuations (8%). Liver function monitoring is required; grade 3/4 events drop survival odds.[2][6]
Who makes it and access details
Jazz Pharmaceuticals markets Zepzelca in the US (approval June 2020). Pricing averages $13,000 per cycle; patient assistance programs cover copays for eligible insured patients. Patents extend exclusivity to 2031, with challenges pending—no generics yet.[7][1]
Sources
[1]: FDA Label for Zepzelca
[2]: NEJM ATLANTIS Trial (2024)
[3]: Trigo et al., Lancet Oncology (2020)
[4]: ClinicalTrials.gov Lurbinectedin Studies
[5]: ASCO Post-approval Analyses
[6]: ESMO Guidelines SCLC
[7]: DrugPatentWatch.com - Zepzelca Patents